MQS Management LLC Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

MQS Management LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,547 shares of the medical research company’s stock, valued at approximately $750,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. XTX Topco Ltd lifted its stake in shares of IQVIA by 16.5% in the 2nd quarter. XTX Topco Ltd now owns 9,487 shares of the medical research company’s stock valued at $2,006,000 after purchasing an additional 1,347 shares during the period. WCG Wealth Advisors LLC raised its stake in IQVIA by 1.3% during the second quarter. WCG Wealth Advisors LLC now owns 17,497 shares of the medical research company’s stock valued at $3,700,000 after buying an additional 224 shares during the last quarter. Seven Eight Capital LP purchased a new position in IQVIA during the second quarter valued at $3,382,000. Hsbc Holdings PLC raised its stake in IQVIA by 18.7% during the second quarter. Hsbc Holdings PLC now owns 469,752 shares of the medical research company’s stock valued at $99,504,000 after buying an additional 73,877 shares during the last quarter. Finally, Blair William & Co. IL raised its stake in IQVIA by 8.8% during the second quarter. Blair William & Co. IL now owns 4,072 shares of the medical research company’s stock valued at $861,000 after buying an additional 328 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 1.1 %

IQV opened at $242.67 on Thursday. The company has a market capitalization of $44.21 billion, a PE ratio of 33.15, a PEG ratio of 2.24 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm’s 50 day simple moving average is $239.74 and its two-hundred day simple moving average is $234.18. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter last year, the company earned $2.22 earnings per share. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent research reports. Royal Bank of Canada initiated coverage on IQVIA in a research note on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price objective for the company. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Robert W. Baird boosted their target price on IQVIA from $235.00 to $251.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 23rd. Finally, The Goldman Sachs Group initiated coverage on shares of IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $266.67.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.